HeavenlyDoor.com Signs Several E-Business Affiliate Agreements

New York, New York, UNITED STATES

NEW YORK, June 12, 2000 (PRIMEZONE) -- HeavenlyDoor.com, Inc. (Nasdaq:HVDC) has signed strategic e-business affiliate agreements with SympathyFlowers.com (http://www.sympathyflowers.com), Classicmemorials.com (http://www.classicmemorials.com), Mooney and Company and The Funeral Fine Art Collection.

HeavenlyDoor.com will capture a percentage of sales from purchases that the funeral planning Web portal refers to its channel partners. SympathyFlowers.com offers customized floral packages, specifically designed for bereavement and sympathy purposes; ClassicMemorials.com offers grave memorials, cremation urns and memorialization accessories; and Mooney and Company offers sympathy and cremation cards, as well as business stationery for the funeral industry.

In addition to earning a percentage of sales from its e-business affiliates, HeavenlyDoor.com will build a co-branded, fully e-commerce enabled web site for The Funeral Fine Art Collection, which will offer HeavenlyDoor.com visitors the opportunity to purchase high-end urns ranging from $1,200 - $4,000 directly from HeavenlyDoor.com. The collection's artwork has been purchased by numerous famous celebrities.

To support increased consumer demand for targeted grief support products and services, HeavenlyDoor.com plans to establish additional relationships with several other targeted e-business affiliates in the near future, while continuing to expand its funeral home customer base.

"Our e-business agreements create new channels of revenue for HeavenlyDoor.com and enhance our ability to support our customers during their time of need," said Lloyd Kagin, President and CEO of HeavenlyDoor.com, Inc. "HeavenlyDoor.com will continue to pursue relationships with other leading e-businesses targeting the funeral industry to enhance our end-user experience and provide a convenient, one-stop shopping resource for grief support and funeral planning," added Kagin.

At www.heavenlydoor.com, consumers can locate a funeral home closest to their needs using geographic search tools, send condolences through sympathy cards and flowers, and shop for funeral products and services from the comfort of their homes or offices. In the near future, HeavenlyDoor.com is expected to launch a series of Internet-based business-to-business (B2B) applications designed to help funeral products and services' vendors to better connect themselves in the marketplace and to capture e-commerce revenues. For more information, visit www.heavenlydoor.com or call 1-212-899-5290.

HeavenlyDoor.com, Inc., the result of a recent merger between Procept, Inc. (formerly NASDAQ SmallCap: PRCT) and Heaven's Door Corporation, a privately held Internet company, is a publicly traded Internet company whose objective is to provide products and services for the elderly and aging baby boomer population, with an initial focus on the pre-planning of funerals, and ultimately the long-term care, assisted living and financial/estate planning industries. The company, through its subsidiary d/b/a Procept, Inc., is developing and seeks to out-license two biotechnology compounds: PRO 2000 Gel and O6-Benzylguanine, both of which have had substantial government support for their clinical trials to date.

Certain statements in this press release constitute ``forward-looking statements'' that involve risks and uncertainties, including those arising under the Company's business strategy; the ability to enter into relationships with funeral homes and other service and product providers; the market acceptance of the Company's web site; the success of the Company in financing efforts; the pursuit of collaborative arrangements for research and development of product candidates, as well as the pursuit of joint development or licensing arrangements with pharmaceutical, diagnostic or instrumentation companies; the research or development of particular products, compounds or technologies; the uncertainty of the results of such development activities and related clinical trials or required regulatory approvals; and the reliance on collaborative partners and governments for development, regulatory or marketing activities.